Caitlin John’s Avadel Pharmaceuticals AVDL Stock Holding History

Caitlin John’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-133	Closed	-$1.87K	–	867
2024 Q2	$1.87K	Buy	+133	New	+$2.17K	﹤0.01%	663

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Caitlin John's AVDL Position: Q3 2024 in Review

Caitlin John sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 133 shares — an estimated $1.87K sold.

Caitlin John first reported a position in AVDL in Q2 2024 and held it in 1 quarter. The position peaked at $1.87K in Q2 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

Caitlin John reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Caitlin John sold 133 Avadel Pharmaceuticals shares in Q3 2024, an estimated $1.87K.
Caitlin John first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Caitlin John's Avadel Pharmaceuticals position peaked at $1.87K in Q2 2024.
176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Caitlin John's 13F filing for Q3 2024, filed 14 Nov 2024.